Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T20:33:28.392Z.
Calculation as of: 2026-10-06T20:33:28.392Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64b8b41d6b5635a3630374b271ba93e5d0b13f976b61d7cdc588ead55f2777d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Vivos Therapeutics, Inc.
Market Cap
$2.14M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
